Top

Published in:

01-08-2015 | Original Article

Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System

Authors: Maria Paola Bertapelle, Mario Vottero, Giulio Del Popolo, Marco Mencarini, Edoardo Ostardo, Michele Spinelli, Antonella Giannantoni, Anna D’Ausilio

Published in: World Journal of Urology | Issue 8/2015

Abstract

Objectives

To assess the relative cost-effectiveness of two therapeutic strategies: one starting with sacral neuromodulation (SNM) versus one starting with Botulinum toxin A (BTX-A) for the management of refractory incontinent idiopathic overactive bladder (OAB) patients, from the perspective of the Italian National Health Service (INHS).

Methods

Direct medical costs (€2011) and benefits (quality-adjusted life years—QALYs) were assessed over a ten-year time frame adapting to the Italian practice a published Markov model. Clinical inputs were based on the published literature and on the expert opinion. Resource consumption rates were provided by clinical experts; unit costs were collected from a single hospital accounting and from standard tariff lists and public prices. Interventional procedures and management of adverse events were costed through a micro-costing approach. The primary outcome was incremental costs per QALYs gained (i.e. differential costs divided by differential benefits). Deterministic (DSA) and probabilistic (PSA) sensitivity analyses were conducted to assess the robustness of the model.

Results

Starting with SNM appears to be cost effective (i.e. under €40.000/QALY) from year three (€21,259/QALY) onwards and becomes dominant (i.e. more effective and less costly) at year ten: cumulative costs were €32,975 for early SNM and €33,309 for early BTX-A, while cumulative QALYs were 7.52 and 6.93, respectively. At year ten, DSA suggests the results robustness and 99.8 % of the PSA iterations fell within the cost-effectiveness threshold.

Conclusions

A therapeutic strategy starting with SNM may be considered cost effective in the midterm and cost saving in the long-term treatment of idiopathic OAB from the INHS perspective.

Abrams P, Cardozo L, Fall M et al (2003) The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 61:37–49PubMedCrossRef

Irwin DE, Milsom I, Kopp Z et al (2006) Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 97:96–100PubMedCrossRef

Irwin DE, Kopp ZS, Aqatep B et al (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108:1132–1138PubMedCrossRef

Lucas MG, Bosch RJ, Burkhard FC et al (2012) EAU guidelines on assessment and nonsurgical management of urinary incontinence. EurUrol 62:1130–1142

Lucas MG, Bosch RJ, Burkhard FC et al (2012) EAU guidelines on surgical treatment of urinary incontinence. EurUrol 62:1118–1129

Arlandis S, Castro D, Errando C et al (2011) Cost-effectiveness of sacral neuromodulation compared to Botulinum neurotoxin A or continued medical management in refractory overactive bladder. Value Health 14:219–228PubMedCrossRef

Leong RK, de Wachter SG, Joore MA et al (2011) Cost-effectiveness analysis of sacral neuromodulation and Botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 108:558–564PubMedCrossRef

Walleser S, Betts C, Hallas N et al (2012) Sacral nerve modulation (SNM) for the treatment of idiopathic refractory overactive bladder: cost-effective in the UK compared to optimal medical therapy, Botulinum toxin A (BoNT-A) and percutaneous tibial nerve stimulation (PTNS). Value Health 15:A354–A355CrossRef

Gruppo di lavoro AIES coordinato da Giovanni Fattore (2009) Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Politiche Sanitarie 10:91–99

10.

Leong RK, De Wachter SG, Nieman FH et al (2011) PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. NeurourolUrodyn 30:1249–1252

11.

Chartier-Kastler E, Ballanger P, Belas M et al (2011) Sacral neuromodulation with InterStim system: results from the French national register. ProgUrol 21:209–217

12.

Groen J, Blok BF, Bosch JL (2011) Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol 186:954–959PubMedCrossRef

13.

Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184:2416–2422PubMedCrossRef

14.

Nitti VW, Dmochowsky R, Herschorn S et al (2013) OnabotulinumtoxinA for the treatment of patients with Overactive Bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189(6):2186–2193

15.

Chapple C, Sievert KD, MacDiarmid S et al (2013) OnabotulinumtoxinA 100U significantly improves all idiopathic Overactive Bladder symptoms and quality of life in patients with Overactive Bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64(2):249–256

16.

Dowson C, Watkins J, Khan MS et al (2012) Repeated Botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. EurUrol 61:834–839

17.

Mohee A, Khan A, Harris N et al (2012) Long-term outcome of the use of intravesical Botulinum toxin for the treatment of overactive bladder. BJU Int 111:106–113PubMedCrossRef

18.

Paletta T, Lucioni C, Volpe M (2010) L’EuroQoL (EQ-5D) per la misura dell’utilità negli studi di farmacoeconomia. Considerazioni metodologiche applicate al caso del paziente in dimissione dopo infarto miocardico. Pharmacoecon Ital Res Artic 12:51–59

19.

Currie CJ, McEwan P, Poole CD et al (2006) The impact of the overactive bladder on health-related utility and quality of life. BJU Int 97:1267–1272PubMedCrossRef

20.

L’informatore farmaceutico – Medicinali 2011. Elsevier, Milano, 2011

21.

Age.Na.S. Prestazioni specialistiche ambulatoriali. Confronto tariffe nazionali ex DM1996 e le tariffe regionali vigenti nel 2009, 2009

22.

Servizio Infermieristico 537. Costituzione della Commissione per il monitoraggio e la prevenzione dell’incontinenza. ASL Trieste. 2006

23.

Scroccaro G, Steffenino G, Marini P et al (2005) La valutazione dei benefici e dei costi dei dispositivi medici. Il caso degli stent medicati. Pharmacoecon Ital Res Artic 7:195–206

24.

Ganz M, Clemens JQ, Anger J et al (2011) A Markov model comparing sacral neuromodulation and Botulinum toxin-A for medicare patients with idiopathic overactive bladder refractory to conservative care. Value Health 14:A211–A214

25.

Hassouna M, Corcos J, Dwyer N et al (2012) Cost-effectiveness of sacral neuromodulation in refractory overactive bladder: a Canadian perspective. J Urol 187(4S):e117

26.

Siddiqui NY, Amundsen CL, Visco AG et al (2009) Cost-effectiveness of sacral neuromodulation versus intravesical Botulinum A toxin for treatment of refractory urge incontinence. J Urol 182:2799–2804PubMedCrossRef

27.

Borawski KM, Foster RT, Webster GD et al (2007) Predicting implantation with a neuromodulator using two different test stimulation techniques: a prospective randomized study in urge incontinent women. NeurourolUrodyn 26:14–18

28.

van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al (2007) Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178:2029–2034PubMedCrossRef

29.

Kessler TM, La FD, Trelle S et al (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. EurUrol 58:865–874

30.

Sahai A, Dowson C, Khan MS et al (2010) Repeated injections of Botulinum toxin-A for idiopathic detrusor overactivity. Urology 75:552–558PubMedCrossRef

31.

Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD (2010) Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology 76(4):835–840PubMedCrossRef

Title: Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System
Authors: Maria Paola Bertapelle
Mario Vottero
Giulio Del Popolo
Marco Mencarini
Edoardo Ostardo
Michele Spinelli
Antonella Giannantoni
Anna D’Ausilio
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1401-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2015

Change in storage symptoms following laser prostatectomy: comparison between photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP)

The comparison of minimally invasive percutaneous nephrolithotomy and retrograde intrarenal surgery for stones larger than 2 cm in patients with a solitary kidney: a matched-pair analysis

Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy

Nutritional predictors of complications following radical cystectomy

Retropubic, laparoscopic and mini-laparoscopic radical prostatectomy: a prospective assessment of patient scar satisfaction

Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)